Advocacy intelligence hub — real-time data for patient organizations
Implantology Institute
National Cancer Institute (NCI) — PHASE2, PHASE3
UNC Lineberger Comprehensive Cancer Center — PHASE2
Thomas Jefferson University — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Neutrexin
Medimmune Oncology, Inc.
Neutrexin
(Trimetrexate glucuronate)Orphan drugstandardMedimmune Oncology, Inc.
Adam Luginbuhl, MD, M.D
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
📍 PHILADELPHIA, PA
Athanassios (Ethan) Argiris
ECOG-ACRIN Cancer Research Group
📍 Mobile, Alabama
Tanguy Seiwert, M.D
University of Chicago Comprehensive Cancer Center P2C
📍 BALTIMORE, MD
K Mosterd, MD, PhD
Maastricht University Medical Center
Omer Kucuk, MD, MD
Barbara Ann Karmanos Cancer Institute
📍 ATLANTA, GA
Ezra Cohen, MD
The University of Chicago Medical Center